2016
Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration
Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.Peer-Reviewed Original ResearchAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugDrug Administration ScheduleEtoposideFemaleHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousMaleMelphalanMiddle AgedTransplantation ConditioningTransplantation, AutologousYoung Adult
2006
Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related Symptoms
Dummer R, Foss F, Dreno B, Bagot M. Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related Symptoms. Seminars In Oncology 2006, 33: 26-32. PMID: 16516673, DOI: 10.1053/j.seminoncol.2005.12.020.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaSkin-directed therapiesEarly-stage diseasePatient-specific factorsT-cell lymphomaReferral centerStage diseaseSystemic therapyTopical chemotherapyTreatment algorithmTherapeutic optionsIndividual patientsLymphoma managementPatientsSpecialized therapiesTherapyBeam radiationChemotherapySymptomsPractical managementUVA irradiationSpecific factorsPhotopheresisLymphomaCarmustine